AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 87 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $355,000 | +80.2% | 154,175 | +270.4% | 0.00% | – |
Q4 2021 | $197,000 | -92.2% | 41,624 | -86.8% | 0.00% | -100.0% |
Q3 2021 | $2,511,000 | -44.6% | 315,823 | -51.5% | 0.01% | -52.4% |
Q2 2021 | $4,534,000 | -51.9% | 651,403 | -45.3% | 0.02% | -51.2% |
Q1 2021 | $9,435,000 | -3.6% | 1,191,239 | -4.2% | 0.04% | -18.9% |
Q4 2020 | $9,784,000 | +11.1% | 1,243,250 | +0.1% | 0.05% | -5.4% |
Q3 2020 | $8,809,000 | -23.7% | 1,242,427 | -0.5% | 0.06% | -30.9% |
Q2 2020 | $11,552,000 | +195.4% | 1,248,915 | +48.8% | 0.08% | +107.7% |
Q1 2020 | $3,911,000 | -38.6% | 839,160 | +0.7% | 0.04% | -11.4% |
Q4 2019 | $6,367,000 | +3.4% | 833,407 | +4.1% | 0.04% | -8.3% |
Q3 2019 | $6,157,000 | +36.4% | 800,607 | +21.5% | 0.05% | +29.7% |
Q2 2019 | $4,513,000 | -25.4% | 658,698 | -12.4% | 0.04% | +27.6% |
Q1 2019 | $6,052,000 | – | 751,806 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 279,678 | $2,587,000 | 10.00% |
Aisling Capital Management LP | 1,691,151 | $15,643,000 | 5.97% |
Samsara BioCapital, LLC | 967,500 | $8,949,000 | 2.88% |
Bain Capital Life Sciences Investors, LLC | 2,700,000 | $24,975,000 | 2.62% |
Soleus Capital Management, L.P. | 369,852 | $3,421,000 | 1.95% |
Nantahala Capital Management | 3,204,830 | $29,645,000 | 0.89% |
Lion Point Capital, LP | 300,000 | $2,775,000 | 0.67% |
Abingworth LLP | 240,500 | $2,221,000 | 0.62% |
Sio Capital Management, LLC | 211,104 | $1,953,000 | 0.57% |
Orbimed Advisors | 4,015,524 | $37,144,000 | 0.52% |